Could a drug cocktail slash deaths from TB of the brain?
NCT ID NCT04145258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase III trial in sub-Saharan Africa tests whether giving higher doses of rifampicin plus linezolid, along with aspirin, can reduce deaths from tuberculous meningitis (TBM) in both HIV-positive and HIV-negative people. About 768 adolescents and adults will receive either the intensified treatment or standard WHO therapy, with or without aspirin. The goal is to see if these additions improve survival over the current standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
high-dose rifampicin, linezolid, and aspirin
What this could lead to
If successful, this could lead to a new standard treatment that lowers the death rate from tuberculous meningitis, a severe brain infection.
What could go wrong
This is a large Phase III trial, but the intensified drugs may cause more side effects, and the benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOUS MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cocody University Hospital
NOT_YET_RECRUITINGAbidjan, Côte d’Ivoire
Contact
-
Dora Nginza Hospital
RECRUITINGPort Elizabeth, South Africa
Contact
-
Kayelitsha District Hospital
RECRUITINGCape Town, South Africa
Contact
-
Livingstone and PE Central Hospitals
RECRUITINGPort Elizabeth, South Africa
Contact
-
Mbarara Regional Reference Hospital
RECRUITINGMbarara, Uganda
Contact
-
Mitchells Plain Hospital
RECRUITINGCape Town, South Africa
Contact
-
Morafeno University Hospital
NOT_YET_RECRUITINGToamasina, Madagascar
Contact
-
New Somerset Hospital
RECRUITINGCape Town, South Africa
Contact
-
Regional Reference Hospital of Kabale
RECRUITINGMbarara, Uganda
Contact
-
Treichville University Hospital
RECRUITINGAbidjan, Côte d’Ivoire
Contact
-
University Hospital Joseph Raseta Befelatanana
RECRUITINGAntananarivo, Madagascar
Contact
-
University Hospital Tambohobe
RECRUITINGFianarantsoa, Madagascar
Contact
-
Yopougon University Hospital
NOT_YET_RECRUITINGAbidjan, Côte d’Ivoire
Contact